Integrum AB
STO:INTEG B
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its Industry Average (33.5), the stock would be worth kr-47.49 (696% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -5.6 | kr7.97 |
0%
|
| Industry Average | 33.5 | kr-47.49 |
-696%
|
| Country Average | 23.9 | kr-33.9 |
-525%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
kr202.1m
|
/ |
Feb 2026
kr-37.8m
|
= |
|
|
kr202.1m
|
/ |
Apr 2026
kr-52.4m
|
= |
|
|
kr202.1m
|
/ |
Apr 2027
kr18.3m
|
= |
|
|
kr202.1m
|
/ |
Apr 2028
kr32.4m
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| SE |
I
|
Integrum AB
STO:INTEG B
|
212.5m SEK | -5.6 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
161.2B USD | 56.4 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.6B USD | 25.1 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 37.4 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
101.9B USD | 22.3 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
84.8B USD | 23.7 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.2B USD | 43.3 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
38.3B EUR | 18.5 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.1B USD | 42.1 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
41.4B USD | 24 | |
| US |
|
Resmed Inc
NYSE:RMD
|
30.9B USD | 20.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 17.4 |
| Median | 23.9 |
| 70th Percentile | 32.1 |
| Max | 8 163.4 |
Other Multiples
Integrum AB
Glance View
Integrum AB engages in the manufacturing of medical devices. The company is headquartered in Moelndal, Vastra Gotalands. The company went IPO on 2017-05-15. The company provides systems for bone-anchored prostheses for individuals with amputations. The Company’s solutions comprise OPRA Implant System, neural prosthetics, phantom limb pain treatment and prosthetic components. The OPRA implant system is based on osseointegration, enabling the direct connection of an artificial limb to the skeleton. The neural prosthetics technology implies ability to directly connect bionic prostheses to the patient’s bone, nerves, and muscles. A method for limb pain treatment implies motor execution of the phantom limb as a treatment, which is aided by machine learning, augmented and virtual reality. The firm provides a variety of prosthetic components required to connect the OPRA Implant System to external prostheses.
